Against the backdrop of a Cas9 patent battle that refuses to die, Editas Medicine is cashing in a chunk of the licensing ...

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, ...

As summer heat turns to cool winds, hopes that this year would bring widespread industry relief have dissipated, with ...

A minority of patients taking Ultragenyx Pharmaceutical’s Wilson disease gene therapy UX701 have come off standard-of-care ...

Ten years after first collecting an FDA approval, it’s time for version number two. | Cologuard Plus represents the next ...

Precision medicines biotech Relay Therapeutics is shedding about 10% of its workforce in efforts to streamline the ...

Prothena, a company focused on neurodegenerative diseases, is shaking up its C-suite. The exec moves were announced just a ...

Mosnodenvir is designed to block interactions between two dengue virus proteins. The vaccine survived J&J’s decision last ...

Siemens Healthineers has received a new go-ahead from the FDA for what the company describes as its first completely ...

One of those companies, a contract research organization focused on genetic medicines called Franklin Biolabs, officially ...

Gritstone bio has brought in bankers to explore “potential value-maximizing strategies” after its phase 2 colorectal cancer ...

Pentixapharm has brought in almost 20 million euros ($22 million) from an IPO, with the German biotech earmarking the ...